MedTrace Logo

Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

NCT00959439 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).

Conditions

Interventions

DRUG

Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)

DRUG

Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)

Sponsors & Collaborators

Principal Investigators

  • Ronald Goldwater, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2002-05-31
Completion
2002-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959439 on ClinicalTrials.gov